GLP-1 Market
LLY $1270.75 ▼ -1.0% NVO $39.06 ▼ -0.7% PFE $29.85 ▼ -0.9% VKTX $26.38 ▼ -1.2% KLRA $12.92 ▲ +0.2% GPCR $22.01 ▼ -3.8% RHHBY $59.11 • 0.0%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Foralumab Nasal

Company
Tiziana Life Sciences LTD
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 22, 2026

Find a Clinical Trial Near Me

See recruiting studies for Foralumab Nasal and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06868628

    A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)

    Not yet reported Tiziana Life Sciences LTD 5 participants Est. completion 2027-04-01 1 site Stand-alone
    Other conditions: Multiple System Atrophy
    View official trial listing →
  • Withdrawn NCT NCT04983446

    In-patient COVID-19 Study of Intranasal Foralumab

    Not yet reported Tiziana Life Sciences LTD Est. completion 2022-12-30
    Other conditions: Covid19, COVID-19 Lower Respiratory Infection, COVID-19 Respiratory Infection
    View official trial listing →
  • Withdrawn NCT NCT05029609

    Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS

    Not yet reported Tiziana Life Sciences LTD Est. completion 2022-12
    Other conditions: Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Multiple Sclerosis
    View official trial listing →
  • Active, not recruiting NCT NCT06292923

    A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

    Not yet reported Tiziana Life Sciences LTD 54 participants Est. completion 2026-10 7 sites Stand-alone
    Other conditions: Secondary Progressive Multiple Sclerosis
    View official trial listing →
  • Available NCT NCT06802328

    Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients

    Tiziana Life Sciences LTD 1 site
    Other conditions: Non-Active Secondary Progressive Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT06879067

    Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers

    Not yet reported Tiziana Life Sciences LTD 27 participants Est. completion 2020-11-09 1 site Stand-alone
    Other conditions: Safety, Tolerability
    View official trial listing →
  • Not yet recruiting NCT NCT07688239

    The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab

    Not yet reported Tiziana Life Sciences LTD 44 participants Est. completion 2027-11 4 sites Stand-alone
    Other conditions: ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis, ALS
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.